Showing results (41-50 of 54) with videos related to
Sort By:
Pageof 6
Immunotherapy|May 31, 2023
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summaryKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.Allergy|November 13, 2021
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension studyMarcus Maurer, Ana Giménez-Arnau, Jonathan A Bernstein, et al.Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.The Journal of Allergy and Clinical Immunology. in Practice|March 18, 2019
Penicillin Allergy Evaluation: A Prospective, Multicenter, Open-Label Evaluation of a Comprehensive Penicillin Skin Test KitRoland Solensky, Joshua Jacobs, Mitchell Lester, et al.American Journal of Clinical Dermatology|May 14, 2022
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)Andrew Blauvelt, Emma Guttman-Yassky, Amy S Paller, et al.JAMA Dermatology|April 19, 2023
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical TrialAmy S Paller, Carsten Flohr, Michael Cork, et al.Respiratory Research|March 20, 2016
A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthmaJeffrey M Harris, Romeo Maciuca, Mary S Bradley, et al.Lancet (London, England)|October 12, 2015
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Eric L Simpson, Lisa A Beck, et al.The Journal of Allergy and Clinical Immunology. in Practice|January 16, 2021
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic DermatitisMark Boguniewicz, Lisa A Beck, Lawrence Sher, et al.JAMA Dermatology|October 23, 2024
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 WeeksAmy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, et al.Pageof 6